Therapeutic Sequencing in Metastatic Renal Cell Carcinoma.

ABSTRACT: The influx of multiple novel therapeutic options in the mRCC field has brought a challenge for treatment sequencing in this disease. In the past few years, cabozantinib, nivolumab and the combination of lenvatinib and everolimus have been approved in the second-line setting. As there is no direct comparison between these agents and the studies have failed to show improved benefit among a biomarker-selected patient population, appropriate patient selection based on clinical factors for individualized therapy is critical. Herein we provide a comprehensive overview of current data from each agent through the discussion of disease biology, clinical trials, potential biomarkers and distilling future perspectives in the field.

SUBMITTER: Maia MC 

PROVIDER: S-EPMC6179120 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature